APA (7th ed.) Citation

Bharath, P., Vignesh, S., & D., T. K. (2026). Computational discovery of lead compounds targeting G1202R-based ALK triple mutations conferring lorlatinib resistance in EML4-ALK variant 3 non-small cell lung cancer. Journal of Applied Pharmaceutical Science, 16(4), 304. https://doi.org/10.7324/JAPS.2026.264285

Chicago Style (17th ed.) Citation

Bharath, Palani, Sivaprakasam Vignesh, and Thirumal Kumar D. "Computational Discovery of Lead Compounds Targeting G1202R-based ALK Triple Mutations Conferring Lorlatinib Resistance in EML4-ALK Variant 3 Non-small Cell Lung Cancer." Journal of Applied Pharmaceutical Science 16, no. 4 (2026): 304. https://doi.org/10.7324/JAPS.2026.264285.

MLA (9th ed.) Citation

Bharath, Palani, et al. "Computational Discovery of Lead Compounds Targeting G1202R-based ALK Triple Mutations Conferring Lorlatinib Resistance in EML4-ALK Variant 3 Non-small Cell Lung Cancer." Journal of Applied Pharmaceutical Science, vol. 16, no. 4, 2026, p. 304, https://doi.org/10.7324/JAPS.2026.264285.